Get the Stockscreener App
0.3983
1.22%
0.0048
After Hours:
.38
-0.0183
-4.59%
Jupiter Neurosciences Inc stock is traded at $0.3983, with a volume of 52,051.
It is up +1.22% in the last 24 hours and down -5.79% over the past month.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
See More
Previous Close:
$0.3935
Open:
$0.3726
24h Volume:
52,051
Relative Volume:
0.17
Market Cap:
$14.45M
Revenue:
-
Net Income/Loss:
$-8.64M
P/E Ratio:
-1.5553
EPS:
-0.2561
Net Cash Flow:
$-5.41M
1W Performance:
+6.95%
1M Performance:
-5.79%
6M Performance:
-73.80%
1Y Performance:
-31.33%
1-Day Range:
$0.3726
$0.3983
1-Week Range:
$0.3461
$0.4144
52-Week Range:
$0.3062
$3.33
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences Inc
Sector
Industry
Phone
(561) 406-6154
Address
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JUNS
Jupiter Neurosciences Inc
|
0.3983 | 14.28M | 0 | -8.64M | -5.41M | -0.2561 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Jupiter Neurosciences Inc Stock (JUNS) Latest News
Stock List: Research Stocks from Around the World - GuruFocus
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 - The Globe and Mail
Jupiter Neurosciences Investor News: Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - The Joplin Globe
Growth Review: Will Jupiter Neurosciences Inc benefit from rising consumer demand2026 Update & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Winners Losers: What are analysts price targets for EMP PRAEarnings Risk Summary & Weekly Breakout Watchlists - baoquankhu1.vn
Rosen Law Firm Encourages Jupiter Neurosciences, Inc. Investors to Inquire About Securities Class Action Investigation – JUNS - Caledonian Record
JUNS PE Ratio & Valuation, Is JUNS Overvalued - Intellectia AI
Forecast Cut: What analysts say about Jupiter Neurosciences Inc stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Swing Trade: Can Avis Budget Group Inc sustain earnings growth2026 Key Lessons & Stepwise Trade Signal Guides - baoquankhu1.vn
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board - The National Law Review
Investment Review: Will Jupiter Neurosciences Inc benefit from rising consumer demandMarket Movers & Safe Entry Point Identification - baoquankhu1.vn
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia Advisory Board - Bitget
Jupiter Neurosciences adds advisors for consumer product expansion By Investing.com - Investing.com Canada
Jupiter Neurosciences adds advisors for consumer product expansion - Investing.com
Jupiter Neurosciences adds advisors for consumer product line By Investing.com - Investing.com South Africa
Jupiter Neurosciences adds advisors for consumer product line - Investing.com
Breakout Move: Is Jupiter Neurosciences Inc forming a bullish divergence2026 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
JUNS SEC FilingsJUPITER NEUROSCIENCES, INC. 10-K, 10-Q, 8-K Forms - Stock Titan
Jupiter Neurosciences, Inc. Advances JOTROL™ Resveratrol Platform for Neuroinflammation Treatments and Launches Nugevia Longevity Supplements 69 70 73 108 - Minichart
Jupiter Neurosciences Delays Annual 10-K Filing - TipRanks
Jupiter Neurosciences 2025 10-K: $21.8K Revenue, $0.00 EPS (net loss $8.64M) - TradingView — Track All Markets
Jupiter Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Jupiter Neurosciences (JUNS) flags going concern risk and expands JOTROL, Nugevia strategy - stocktitan.net
[NT 10-K] JUPITER NEUROSCIENCES, INC. SEC Filing - stocktitan.net
Breakout Move: Will Jupiter Neurosciences Inc benefit from geopolitical trends2026 Levels & Daily Momentum Trading Reports - baoquankhu1.vn
North Country Limousine Opens 2026 Wine Tour Reservations for Long Island’s North Fork - weeklyvoice.com
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2 - The Norfolk Daily News
Jupiter Neurosciences, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Will The GEO Group Inc outperform during market ralliesPortfolio Value Summary & Weekly Return Optimization Plans - baoquankhu1.vn
Nasdaq Moves: Does Jupiter Neurosciences Inc outperform in volatile marketsQuarterly Investment Review & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Growth Recap: How is Mersana Therapeutics Inc managing supply chain issues2026 Market Outlook & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Market Moves: What analysts say about Jupiter Neurosciences Inc stockWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
JUPITER NEUROSCIENCES INC (JUNS) Fundamental Analysis & Valuation - ChartMill
Buyback Watch: Can ACDC expand its profit margins2026 Catalysts & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Aug Patterns: Is Jupiter Neurosciences Inc benefiting from interest rate changesShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn
Centri - TMX Newsfile
EDGAR Filing Documents for 0001493152-24-048687 - SEC.gov
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
If You Invested $1,000 in JUPITER NEUROSCIENCES, INC. (JUNS) - Stock Titan
Jupiter Neurosciences, Inc.: Fundamental Analysis and Financial Ratings | JUNS | US48208B2034 - marketscreener.com
JUNS Forecast, Price Target & Analyst Ratings | JUPITER NEUROSCIENCES INC (NASDAQ:JUNS) - ChartMill
CEO Moves: Is Jupiter Neurosciences Inc benefiting from interest rate changesWeekly Profit Recap & Fast Gain Stock Tips - baoquankhu1.vn
Jupiter Neurosciences Approaches Critical Clinical Juncture () - aktiencheck.de
Rare disease spotlight: Friedreich ataxia moves beyond mitochondrial bandages - BioCentury
Market Overview: Can Jupiter Neurosciences Inc. reach all time highs this yearGap Up & Scalable Portfolio Growth Methods - baoquankhu1.vn
Trading Action: Is Jupiter Neurosciences Inc forming a double bottomMarket Movers & Weekly High Return Forecasts - baoquankhu1.vn
Bull Bear: What is the earnings history of Jupiter Neurosciences IncTrend Reversal & Technical Buy Zone Confirmations - baoquankhu1.vn
Momentum Shift: How do insiders feel about Jupiter Neurosciences IncJuly 2025 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
Buyback Watch: Will Jupiter Neurosciences Inc face regulatory challengesJuly 2025 Big Picture & Daily Profit Focused Screening - baoquankhu1.vn
Jupiter Neurosciences Inc Stock (JUNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):